S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.
Leandro de Padua Silva,Marcos de Lima,Hagop M. Kantarjian,Richard E. Champlin,Stefan Faderl,Sergio Giralt,Partow Kebriaei,Jan Davisson,Eli Estey,Guillermo Garcia-Manero,Jean Pierre J. Issa,Farhad Ravandi +11 more
TL;DR: It is concluded that prior therapy with hypomethylating agents may potentially improve the outcome of allogeneic transplant in MDS through enhancement of graft versus leukemia effect and should be examined prospectively.
Journal ArticleDOI
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Jorge M. Ramos Perez,Tapan M. Kadia,Guillermo Montalban-Bravo,Stefan Faderl,Koji Sasaki,Naval Daver,Courtney D. DiNardo,Lucia Masarova,Alessandra Ferrajoli,Elias Jabbour,Gautham Borthakur,Hind Al Azzawi,Naveen Pemmaraju,Marina Konopleva,Sherry Pierce,Guillermo Garcia-Manero,Michael Andreeff,Hagop M. Kantarjian,Farhad Ravandi,Yesid Alvarado +19 more
TL;DR: A single institution, pilot study enrolling pts with CD33 positive R/R AML, post-HMA failure High-Risk MDS, and pts with newly diagnosed secondary AML after receiving HMA therapy to determine the safety and efficacy of CPX-351 in combination with GO.
Journal ArticleDOI
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes
Naveen Pemmaraju,Hagop M. Kantarjian,Jorge E. Cortes,Madeleine Duvic,Joseph D. Khoury,Keyur P. Patel,Naval Daver,Susan O'Brien,Sherry Pierce,Guillermo Garcia-Manero,Elias Jabbour,Nitin Jain,Stefan Faderl,Deborah A. Thomas,Arthur E. Frankel,Muzaffar H. Qazilbash,Marina Konopleva +16 more
TL;DR: A clinically validated 28-gene molecular panel (next-generation sequencing for commonly mutated genes in myeloid malignancies) is now being performed prospectively on all new pts with BPDCN seen at the authors' institution (thus far, n=9); notably, all 9 have expressed some form of TET2 mutation.
Journal ArticleDOI
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: Phase 3 post hoc analyses
Tara L. Lin,David A. Rizzieri,Daniel H. Ryan,Gary J. Schiller,Jonathan E. Kolitz,Geoffrey L. Uy,Donna E. Hogge,Scott R. Solomon,Matthew J. Wieduwilt,Robert J. Ryan,Stefan Faderl,Jorge E. Cortes,Jorge E. Cortes,Jeffrey E. Lancet +13 more
TL;DR: CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) as mentioned in this paper.
Journal ArticleDOI
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
Wendy Stock,Samir D. Undevia,Carol Bivins,Farhad Ravandi,Olatoyosi Odenike,Stefan Faderl,Elizabeth Rich,Gautam Borthakur,Lucy A. Godley,Srdan Verstovsek,Andrew S. Artz,William G. Wierda,Richard A. Larson,Yanming Zhang,Jorge E. Cortes,Mark J. Ratain,Francis J. Giles +16 more
TL;DR: XK469R induced hematological responses in patients with refractory leukemia at tolerable doses at dose levels of 1,400, 1,750, 2,200, and 2,750 mg and no correlation was observed between the development of DLT and pharmacokinetics.